As early as 2012, Zimmer contributed to the development of a drug based on the compound 5-Aminolevulinic acid for use in the treatment of actinic keratoses. The spin-off Zimmer BioTech has been active since October 2016 and is funded by Bonn-based High-Tech Gründerfonds, Germany’s largest seed stage investor. Alevin deep, the first drug to be developed by Zimmer BioTech, is expected to receive approval by 2020.
Spin-off of Neu-Ulm-based medical device producer develops drug to treat skin cancer – Zimmer BioTech expands development team
Neu-Ulm-based medical device producer and High-Tech Gründerfonds found spin-off Zimmer BioTech: New therapy to combat skin cancer